In the ATTAIN-1 phase 3, randomized trial, the use of orforglipron, an oral glucagon-like peptide-1 receptor agonist, led to significant mean body-weight reductions in patients with obesity, as compared with placebo
Stock is held and dispatched AU-domestic no inbound customs handling
Backed by over 15 years of clinical research and expertise in sustainable, behavior-driven weight management
GLP-1 receptor agonists confer no increased rates of IBD exacerbation among patients with IBD
The questions that matter more, and the ones I get less often, are the ones this article is built to answer: how do these medications actually differ, who should choose which one, what should you expect from treatment, and how do you tell a careful clinical program apart from a prescription mill
It does not mean the compound has stopped working